ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

5.37
0.03
(0.56%)
Closed January 05 4:12PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
5.37
Bid
5.37
Ask
5.40
Volume
22,259
5.35 Day's Range 5.41
5.09 52 Week Range 6.23
Market Cap
Previous Close
5.34
Open
5.35
Last Trade
56
@
5.37
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
121,195
Shares Outstanding
101,170,000
Dividend Yield
-
PE Ratio
-32.33
Earnings Per Share (EPS)
-0.17
Revenue
331.1M
Net Profit
-16.84M

About Knight Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Montreal, Quebec, Can
Founded
-
Knight Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker GUD. The last closing price for Knight Therapeutics was $5.34. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 5.09 to $ 6.23.

Knight Therapeutics currently has 101,170,000 shares outstanding. The market capitalization of Knight Therapeutics is $540.25 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of -32.33.

GUD Latest News

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug...

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico

MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate...

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has...

Knight Therapeutics Reports Third Quarter 2024

MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate...

Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s...

Knight Therapeutics Reports Second Quarter 2024

MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call

MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024...

Knight Announces Normal Course Issuer Bid

MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "),  a leading pan-American (ex-US) specialty pharmaceutical company, announced today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.122.285714285715.255.415.25599665.32475498CS
40.030.5617977528095.345.415.11667865.24228569CS
12-0.41-7.093425605545.785.825.091211955.29622638CS
26-0.35-6.118881118885.726.235.09877185.47940628CS
520.234.474708171215.146.235.09782325.53602788CS
1560.061.129943502825.316.234.281097595.2857133CS
260-2.28-29.80392156867.658.124.282039945.69048328CS

GUD - Frequently Asked Questions (FAQ)

What is the current Knight Therapeutics share price?
The current share price of Knight Therapeutics is $ 5.37
How many Knight Therapeutics shares are in issue?
Knight Therapeutics has 101,170,000 shares in issue
What is the market cap of Knight Therapeutics?
The market capitalisation of Knight Therapeutics is CAD 540.25M
What is the 1 year trading range for Knight Therapeutics share price?
Knight Therapeutics has traded in the range of $ 5.09 to $ 6.23 during the past year
What is the PE ratio of Knight Therapeutics?
The price to earnings ratio of Knight Therapeutics is -32.33
What is the cash to sales ratio of Knight Therapeutics?
The cash to sales ratio of Knight Therapeutics is 1.64
What is the reporting currency for Knight Therapeutics?
Knight Therapeutics reports financial results in CAD
What is the latest annual turnover for Knight Therapeutics?
The latest annual turnover of Knight Therapeutics is CAD 331.1M
What is the latest annual profit for Knight Therapeutics?
The latest annual profit of Knight Therapeutics is CAD -16.84M
What is the registered address of Knight Therapeutics?
The registered address for Knight Therapeutics is 3400 DE MAISONNEUVE W, SUITE 1055, MONTREAL, QUEBEC, H3Z 3B8
What is the Knight Therapeutics website address?
The website address for Knight Therapeutics is www.gudknight.com
Which industry sector does Knight Therapeutics operate in?
Knight Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DIAMStar Diamond Corporation
$ 0.025
(25.00%)
17.1k
CSCICOSCIENS Biopharma Inc
$ 4.80
(22.14%)
11.2k
DII.BDorel Industries Inc
$ 4.88
(20.49%)
33.64k
ORVOrvana Minerals Corp
$ 0.28
(16.67%)
104.72k
YRBYorbeau Resources Inc
$ 0.04
(14.29%)
671k
FLNTFlint Corporation
$ 0.025
(-16.67%)
17k
RTGRTG Mining Inc
$ 0.03
(-14.29%)
544.49k
TWMTidewater Midstream and Infrastructure Ltd
$ 0.15
(-11.76%)
541.46k
EXROExro Technologies Inc
$ 0.13
(-10.34%)
676.19k
ASTLAlgoma Steel Group Inc
$ 12.92
(-7.58%)
196.97k
TDToronto Dominion Bank
$ 77.79
(1.69%)
17.95M
VRNVeren Inc
$ 7.48
(-1.32%)
6.26M
CNQCanadian Natural Resources Ltd
$ 45.61
(0.95%)
4.64M
ACAir Canada
$ 22.31
(-0.13%)
3.84M
BBBlackBerry Limited
$ 5.34
(-3.09%)
3.79M

GUD Discussion

View Posts
sumotrader sumotrader 9 years ago
Loaded 1600 more shares today. GUD is about to take off.
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
This must be some sort of record,.. " the Company reported revenues of $109,608 and net income of $124,981,439."

http://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
Knight Therapeutics GUD.TO : Mackie Research starts with buy rating; target price of C$12

http://www.investorvillage.com/groups.asp?mb=6781&mn=83648&pt=msg&mid=14732670
👍️0
OneStepAhead OneStepAhead 10 years ago
On a tear
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
GOD is GUD. :)
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
KHTRF is the OTC Ticker for Americans
or
GUD on the TSX for Canadians


LONG on this one.
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
GUD is flying along nicely,.. Paladin II is in GUD hands, Goodman building another BEAST!
👍️0
OneStepAhead OneStepAhead 10 years ago
GUD Knight Therapeutics

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX:GUD) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc., National Bank Financial Inc., Laurentian Bank Securities Inc., Bloom Burton & Co., Clarus Securities Inc., Mackie Research Capital Corporation and TD Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 11,111,120 common shares of the Company (the "Common Shares") at a price of $6.75 per Common Share for gross proceeds to Knight of $75,000,060 (the "Offering"). In addition, the Underwriters will have the option, exercisable for a period of 30 days after the closing date, to acquire up to an aggregate of 1,666,668 additional Common Shares ($11,250,009) at the offering price to cover over-allotments, if any (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering shall be $86,250,069.

http://www.marketwired.com/press-release/knight-therapeutics-enters-into-agreement-75-million-bought-deal-common-shares-tsx-gud-1973898.htm
👍️0
OneStepAhead OneStepAhead 10 years ago
GUD Knight Therapeutics

After selling off his specialty pharmaceutical company Paladin Labs Inc. in a deal worth $3-billion, Montreal entrepreneur Jonathan Goodman is starting from scratch with a new drug distribution venture.

http://www.theglobeandmail.com/globe-investor/investment-ideas/a-fresh-stock-with-a-veteran-face/article17189152/
👍️0
Greedy G Greedy G 10 years ago
TNEN:

http://stockcharts.com/h-sc/ui?s=TNEN&p=D&b=5&g=0&id=p74917584188
👍️0

Your Recent History

Delayed Upgrade Clock